Literature DB >> 21391978

Functional, morphological and molecular characterization of bladder dysfunction in streptozotocin-induced diabetic mice: evidence of a role for L-type voltage-operated Ca2+ channels.

L O S Leiria1, F Z T Mónica, F D G F Carvalho, M A Claudino, C F Franco-Penteado, A Schenka, A D Grant, G De Nucci, E Antunes.   

Abstract

BACKGROUND AND
PURPOSE: Diabetic cystopathy is one of the most common and incapacitating complications of diabetes mellitus. This study aimed to evaluate the functional, structural and molecular alterations of detrusor smooth muscle (DSM) in streptozotocin-induced diabetic mice, focusing on the contribution of Ca(2+) influx through L-type voltage-operated Ca(2+) channels (L-VOCC). EXPERIMENTAL APPROACH: Male C57BL/6 mice were injected with streptozotocin (125 mg·kg(-1) ). Four weeks later, contractile responses to carbachol, α,β-methylene ATP, KCl, extracellular Ca(2+) and electrical-field stimulation were measured in urothelium-intact DSM strips. Cystometry and histomorphometry were performed, and mRNA expression for muscarinic M(2) /M(3) receptors, purine P2X1 receptors and L-VOCC in the bladder was determined. KEY
RESULTS: Diabetic mice exhibited higher bladder capacity, frequency, non-void contractions and post-void pressure. Increased bladder weight, wall thickness, bladder volume and neural tissue were observed in diabetic bladders. Carbachol, α,β-methylene ATP, KCl, extracellular Ca(2+) and electrical-field stimulation all produced greater DSM contractions in diabetic mice. The L-VOCC blocker nifedipine almost completely reversed the enhanced DSM contractions in bladders from diabetic animals. The Rho-kinase inhibitor Y27632 had no effect on the enhanced carbachol contractions in the diabetic group. Expression of mRNA for muscarinic M(3) receptors and L-VOCC were greater in the bladders of diabetic mice, whereas levels of M(2) and P2X1 receptors remained unchanged. CONCLUSIONS AND IMPLICATIONS: Diabetic mice exhibit features of urinary bladder dysfunction, as characterized by overactive DSM and decreased voiding efficiency. Functional and molecular data suggest that overactive DSM in diabetes is the result of enhanced extracellular Ca(2+) influx through L-VOCC.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21391978      PMCID: PMC3144540          DOI: 10.1111/j.1476-5381.2011.01311.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  49 in total

Review 1.  Diabetic autonomic neuropathy.

Authors:  Aaron I Vinik; Raelene E Maser; Braxton D Mitchell; Roy Freeman
Journal:  Diabetes Care       Date:  2003-05       Impact factor: 19.112

Review 2.  Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson; Jerry J Buccafusco; Christopher Chapple; William Chet de Groat; Alison D Fryer; Gary Kay; Alan Laties; Neil M Nathanson; Pankaj Jay Pasricha; Alan J Wein
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 3.  Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy.

Authors:  Naoki Yoshimura; Michael B Chancellor; Karl-Erik Andersson; George J Christ
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

Review 4.  Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract.

Authors:  George J Christ; Karl-Erik Andersson
Journal:  Neurourol Urodyn       Date:  2007-10       Impact factor: 2.696

5.  The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study.

Authors:  Karin S Coyne; Chris C Sexton; Debra E Irwin; Zoe S Kopp; Con J Kelleher; Ian Milsom
Journal:  BJU Int       Date:  2008-06       Impact factor: 5.588

6.  Oxidant driven signaling pathways during diabetes: role of Rac1 and modulation of protein kinase activity in mouse urinary bladder.

Authors:  Deepali Pitre Poladia; John Anthony Bauer
Journal:  Biochimie       Date:  2004-08       Impact factor: 4.079

7.  Evidence for purinergic neurotransmission in human urinary bladder affected by interstitial cystitis.

Authors:  S Palea; W Artibani; E Ostardo; D G Trist; C Pietra
Journal:  J Urol       Date:  1993-12       Impact factor: 7.450

8.  Longitudinal studies of time-dependent changes in both bladder and erectile function after streptozotocin-induced diabetes in Fischer 344 male rats.

Authors:  Arnold Melman; Elena Zotova; Mimi Kim; Joseph Arezzo; Kelvin Davies; Michael DiSanto; Moses Tar
Journal:  BJU Int       Date:  2009-04-15       Impact factor: 5.588

Review 9.  Therapeutic receptor targets for lower urinary tract dysfunction.

Authors:  Naoki Yoshimura; Yasuhiro Kaiho; Minoru Miyazato; Takakazu Yunoki; Changfeng Tai; Michael B Chancellor; Pradeep Tyagi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-21       Impact factor: 3.000

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  21 in total

Review 1.  Stimulators and activators of soluble guanylate cyclase for urogenital disorders.

Authors:  Fabiola Z Mónica; Edson Antunes
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

Review 2.  Big-conductance Ca2+-activated K+ channels in physiological and pathophysiological urinary bladder smooth muscle cells.

Authors:  Shankar P Parajuli; Yun-Min Zheng; Robert Levin; Yong-Xiao Wang
Journal:  Channels (Austin)       Date:  2016-04-21       Impact factor: 2.581

Review 3.  Urinary bladder smooth muscle ion channels: expression, function, and regulation in health and disease.

Authors:  John Malysz; Georgi V Petkov
Journal:  Am J Physiol Renal Physiol       Date:  2020-07-06

4.  Urinary dysfunction in transgenic sickle cell mice: model of idiopathic overactive bladder syndrome.

Authors:  Serkan Karakus; Uzoma A Anele; Fábio H Silva; Biljana Musicki; Arthur L Burnett
Journal:  Am J Physiol Renal Physiol       Date:  2019-06-19

Review 5.  Research Findings on Overactive Bladder.

Authors:  Phani B Patra; Sayani Patra
Journal:  Curr Urol       Date:  2015-05-20

6.  Pharmacological inhibition of myostatin/TGF-β receptor/pSmad3 signaling rescues muscle regenerative responses in mouse model of type 1 diabetes.

Authors:  Jaemin Jeong; Michael J Conboy; Irina M Conboy
Journal:  Acta Pharmacol Sin       Date:  2013-06-17       Impact factor: 6.150

7.  The effect of hypercholesterolemia on carbachol-induced contractions of the detrusor smooth muscle in rats: increased role of L-type Ca2+ channels.

Authors:  Zeynep Dicle Balkanci; Bilge Pehlivanoğlu; Sibel Bayrak; Ismail Karabulut; Serkan Karaismailoğlu; Ayşen Erdem
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-08-07       Impact factor: 3.000

8.  Effect of type II diabetes on male rat bladder contractility.

Authors:  Derek M Kendig; Hillevi K Ets; Robert S Moreland
Journal:  Am J Physiol Renal Physiol       Date:  2016-01-28

9.  Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice.

Authors:  Luiz O Leiria; Carolina Sollon; Marina C Calixto; Letícia Lintomen; Fabíola Z Mónica; Gabriel F Anhê; Gilberto De Nucci; Angelina Zanesco; Andrew D Grant; Edson Antunes
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

10.  Transcutaneous electrical nerve stimulation (TENS) improves the diabetic cytopathy (DCP) via up-regulation of CGRP and cAMP.

Authors:  Liucheng Ding; Tao Song; Chaoran Yi; Yi Huang; Wen Yu; Lin Ling; Yutian Dai; Zhongqing Wei
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.